LSE%3AAZN

AstraZeneca spends US$1.05b to acquire Amolyt Pharma and boost its rare disease portfolio

Global pharmaceutical company AstraZeneca (LSE: AZN) will part with US$1.05 billion to buy-out French biotech Amolyt Pharma, which is focused on the development of novel treatments for rare endocrine diseases. Under the terms of the transaction, AstraZeneca will acquire all of Amolyt’s outstanding shares on a cash and debt-free basis. It will include an US$800 […]